A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)

Trial Profile

A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Zuretinol acetate (Primary)
  • Indications Leber congenital amaurosis; Retinitis pigmentosa
  • Focus Registrational; Therapeutic Use
  • Sponsors Novelion Therapeutics
  • Most Recent Events

    • 10 Dec 2016 Status changed from planning to recruiting.
    • 01 Nov 2016 According to a QLT media release, the company is planning to initiate this trial in the fourth quarter of 2016.
    • 22 Apr 2016 According to a QLT media release, this trial is expected to initiate in the third quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top